Herpes zoster (shingles) is caused by reactivation of the varicella-zoster (chickenpox) virus and typically manifests as a rash. A person’s risk for developing shingles and complications from an infection increases sharply after 50 years of age.
Complications include nerve pain in the area where shingles occurs, vision problems, hearing problems, swelling of the brain and bacterial infections. Vaccines against shingles help prevent the reactivation of the latent chickenpox virus; therefore, helping to prevent shingles.
The investigational vaccine, called Zoster-1018, is manufactured by Dynavax and may help protect people from getting shingles. The investigational vaccine will be compared to the already approved Shingrix vaccine.
If this investigational vaccine can elicit a similar immune response to that of the approved Shingrix vaccine it could provide adults access to another shingles vaccine with improved tolerability and similar efficacy and safety.
You will be reimbursed for your participation.
You may be eligible for this study if you:
The Zoster-1018 study will last for up to 15 months and includes:
